Request Demo

Last update 08 May 2025

SSG Hospital & Medical College

Education|India

Last update 08 May 2025

Overview

Pipeline

Deal

Translational Medicine

Overview

Clinical Trials associated with SSG Hospital & Medical College

CTRI/2021/06/033987

/ Not yet recruitingNot ApplicableIIT

A Comparative study of Oropharyngeal leak pressure by LMA ProtectorTM with cuff pilot vs LMA SupremeTM in paralyzed patients â?? A prospective randomized clinical study.

Start Date10 Jun 2021

Sponsor / Collaborator

SSG Hospital & Medical College

100 Clinical Results associated with SSG Hospital & Medical College

0 Patents (Medical) associated with SSG Hospital & Medical College

Literatures (Medical) associated with SSG Hospital & Medical College

12 Nov 2024·Circulation

Abstract 4147132: Impact of Cannabis Use Disorder on Major Adverse Cardiovascular Events in Hospitalized Young Female Patients with Established Cardiovascular Disease Risk: A Nationwide Analysis from 2016-2020

Author: Amin, Juhi ; Mellacheruvu, Sai Priyanka ; Krishnakumar, Manaswini ; Desai, Rupak ; Pinnamaneni, Monitha ; Sawhney, Aanchal ; Mody, Shefali

Introduction: Cannabis use disorder (CUD) has been associated with major adverse cardiac events (MACE). Additionally, preexisting cardiovascular disease (CVD) poses a major threat to young female patients, but the impact of CUD on MACE remains largely unexplored.Methodology: A retrospective cohort study was undertaken, utilizing data from the National Inpatient Sample dataset spanning from 2016 to 2020. Female patients aged 18-45 years with CVD risk factors (Hypertension, Diabetes Mellitus, Hyperlipidemia, Obesity) were divided into two groups: those with cannabis use disorder (CUD+) and those without (CUD-). Demographic characteristics, comorbidities, and MACE (myocardial infarction (MI), atrial fibrillation (AF), venous thromboembolism (VTE), cardiac arrest (CA), stroke, and all-cause mortality) were explored. Multivariable regression analysis was performed for all the outcomes reported under MACE.Results: Of the 7,245,508 hospitalized young females with CVD risk factors, 3.5% had CUD. CUD+ group was younger (31 vs. 33 years), had more Black patients (37.2 vs. 25.1%) and were more likely to be using Medicaid (59.2 vs. 42.4%). Comorbidities such as complicated diabetes (19.6 vs 13%), smoking (29.4 vs 15.7%), chronic pulmonary disease (22.4 vs 15.2%), drug abuse (64.1 vs 3.7%), alcohol use (10.1 vs 1.8%), and cocaine use (9.2 vs 0.7%) had higher prevalence in CUD+ group (p<0.001). Higher prevalence of MI, CA, and stroke in the CUD+ group, and secondary outcomes showed lower cost of hospitalization, similar length of stay, and a higher number of patient transfers to intermediate care facilities. Multivariable analysis showed that CUD was associated with higher odds of stroke (aOR 1.20) and lower odds for VTE, CA and AF.Conclusion: Young female patients with CUD and established CVD risk factors present a unique clinical profile. While CUD seems to lower the odds of certain cardiovascular events, it significantly heightens the risk of stroke. This further increases the necessity for interventions and healthcare policies aimed at this specific population.

01 Apr 2024·Delhi Journal of Ophthalmology

Enhancing Eye Care: The Significance of National Accreditation Board for Hospitals and Healthcare Providers Accreditation in Ophthalmology

Author: Shah, Jigish ; Mehta, Margeyi M.

01 Mar 2024·Indian Journal of Pharmacology

Prescription-based cost analysis of medicines for cardiovascular risk factors at Indian Council of Medical Research-Rational Use of Medicine Centre Hospitals of India

Article

Author: Gupta, Pooja ; Cherian, Jerin Jose ; Dikshit, Harihar ; Samanta, Kalyan ; Prakash, Ajay ; Bhattacharya, Manjari ; Tripathi, Raakhi ; Jain, Samriti ; Kaushal, Sandeep ; Trivedi, Niyati ; Roy, Sukalyan Saha ; Kumar, Rajiv ; Medhi, Bikash ; Chatterjee, Nabendu Sekhar ; Arora, Shalini ; Shah, Prashant ; Kamat, Sandhya ; Jhaj, Ratinder ; Tripathi, C. D. ; Chugh, Preeta Kaur ; Chatterjee, Suparna ; Banerjee, Aditya ; Mishra, Hitesh ; Samuel, Madhulika Peter ; Kshirsagar, Nilima Arun ; Wasan, Himika ; Gauthaman, Jeevitha ; Chauhan, Janki ; Bright, Heber Rew ; Badyal, Dinesh Kumar ; Chandy, Sujith J. ; Joshi, Rupa ; Mathaiyan, Jayanthi ; Parmar, Urwashi ; Shetty, Yashashri ; Ranjalkar, Jaya ; Gupta, Kanchan ; Ramasamy, Raveendran

AbstractOBJECTIVES:India has taken several initiatives to provide health care to its population while keeping the related expenditure minimum. Since cardiovascular diseases are the most prevalent chronic conditions, in the present study, we aimed to analyze the difference in prices of medicines prescribed for three cardiovascular risk factors, based on (a) listed and not listed in the National List of Essential Medicines (NLEM) and (b) generic and branded drugs.MATERIALS AND METHODS:Outpatient prescriptions for diabetes mellitus, hypertension, and dyslipidemia were retrospectively analyzed from 12 tertiary centers. The prices of medicines prescribed were compared based on presence or absence in NLEM India-2015 and prescribing by generic versus brand name. The price was standardized and presented as average price per medicine per year for a given medicine. The results are presented in Indian rupee (INR) and as median (range).RESULTS:Of the 4,736 prescriptions collected, 843 contained oral antidiabetic, antihypertensive, and/or hypolipidemic medicines. The price per medicine per year for NLEM oral antidiabetics was INR 2849 (2593–3104) and for non-NLEM was INR 5343 (2964–14364). It was INR 806 (243–2132) for generic and INR 3809 (1968–14364) for branded antidiabetics. Antihypertensives and hypolipidemics followed the trend. The price of branded non-NLEM medicines was 5–22 times higher compared to generic NLEM which, for a population of 1.37 billion, would translate to a potential saving of 346.8 billion INR for statins. The variability was significant for sulfonylureas, angiotensin receptor blockers, beta-blockers, diuretics, and statins (P < 0.0001).CONCLUSION:The study highlights an urgent need for intervention to actualize the maximum benefit of government policies and minimize the out-of-pocket expenditure on medicines.

100 Deals associated with SSG Hospital & Medical College

100 Translational Medicine associated with SSG Hospital & Medical College

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 12 May 2026

No data posted

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

SSG Hospital & Medical College

Overview

Related

Corporation Tree

Pipeline

Pipeline Snapshot as of 12 May 2026

Deal

Translational Medicine

Profit

Grant & Funding(NIH)

Investment

Financing